NasdaqGS - Nasdaq Real Time Price USD

Apellis Pharmaceuticals, Inc. (APLS)

Compare
33.19 +0.45 (+1.37%)
At close: December 13 at 4:00:02 PM EST
33.49 +0.30 (+0.90%)
After hours: 7:52:16 PM EST
Loading Chart for APLS
DELL
  • Previous Close 32.74
  • Open 32.60
  • Bid 33.12 x 600
  • Ask 33.26 x 300
  • Day's Range 31.76 - 33.50
  • 52 Week Range 24.34 - 73.80
  • Volume 4,152,402
  • Avg. Volume 3,327,634
  • Market Cap (intraday) 4.129B
  • Beta (5Y Monthly) 0.87
  • PE Ratio (TTM) --
  • EPS (TTM) -2.03
  • Earnings Date Feb 25, 2025 - Mar 3, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 45.75

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

www.apellis.com

702

Full Time Employees

December 31

Fiscal Year Ends

Recent News: APLS

View More

Performance Overview: APLS

Trailing total returns as of 12/13/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

APLS
44.55%
S&P 500
26.86%

1-Year Return

APLS
46.26%
S&P 500
30.31%

3-Year Return

APLS
20.75%
S&P 500
28.42%

5-Year Return

APLS
21.71%
S&P 500
90.97%

Compare To: APLS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: APLS

View More

Valuation Measures

Annual
As of 12/13/2024
  • Market Cap

    4.13B

  • Enterprise Value

    4.20B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.71

  • Price/Book (mrq)

    17.41

  • Enterprise Value/Revenue

    5.88

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -34.97%

  • Return on Assets (ttm)

    -16.23%

  • Return on Equity (ttm)

    -106.56%

  • Revenue (ttm)

    715.22M

  • Net Income Avi to Common (ttm)

    -250.1M

  • Diluted EPS (ttm)

    -2.03

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    403.69M

  • Total Debt/Equity (mrq)

    198.40%

  • Levered Free Cash Flow (ttm)

    -140.21M

Research Analysis: APLS

View More

Company Insights: APLS

Research Reports: APLS

View More

People Also Watch